Focused On-demand Library for Transcription factor ETV6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P41212

UPID:

ETV6_HUMAN

Alternative names:

ETS translocation variant 6; ETS-related protein Tel1

Alternative UPACC:

P41212; A3QVP6; A8K076; Q9UMF6; Q9UMF7; Q9UMG0

Background:

Transcription factor ETV6, known as ETS translocation variant 6 or ETS-related protein Tel1, plays a pivotal role in hematopoiesis and has been implicated in malignant transformation. This protein functions as a transcriptional repressor, binding to the DNA sequence 5'-CCGGAAGT-3', and is crucial in the regulation of gene expression involved in cell growth and development.

Therapeutic significance:

ETV6 is directly involved in the pathogenesis of several hematologic disorders, including Myeloproliferative disorder chronic with eosinophilia, characterized by malignant eosinophils proliferation, and Acute myelogenous leukemia, a severe form of leukemia marked by maturational arrest of hematopoietic precursors. Additionally, it plays a role in Thrombocytopenia 5, a disorder leading to decreased platelet counts and increased risk of malignancies. Understanding the role of ETV6 could open doors to potential therapeutic strategies targeting these diseases.